扫描下面的二维码:

二维码

"热点聚焦"标签列表

[APASL2011]Liver Fibrosis therapies: Getting to the source of the problem2011-02-25

[APASL2011]HCV Non responders triple therapy for Non responders.2011-02-25

[APASL2011]HBsAg: Ultimate endpoint and ultimate predictor of response?2011-02-25

[APASL2011]HBV Population patterns2011-02-25

[APASL2011]Eating yourself to survival2011-02-25

[APASL2011]What to do for people with HCC contraindicated for people unsuitable for surgery?2011-02-25

[APASL2011]Hepatopulmonary Syndrome and Portopulmonary Hypertension: Modern Concepts of Pathogenesis2011-02-23

[APASL2011]Recent Advances in Imaging Diagnosis and Staging of HCC2011-02-23

[APASL2011]Large HCC and Downstaging - A Difficult But Challenging Task2011-02-23

[APASL2011]Raising the Barrier to HCV Resistance2011-02-23

[APASL2011]We Need More Globally Cohesive HBV Treatment Management Strategies2011-02-23

[APASL2011]Refractory Cirrhotic Ascites, Hyponatremia and Acute Kidney Injury in Cirrhosis2011-02-23

[APASL2011]Autoimmune liver diseases — from bench to bed-side2011-02-23

[APASL2011]Stem Cells in Liver Carcinogenesis2011-02-23

[APASL2011]Emerging trends in the Management of Viral Hepatitis2011-02-23

[APASL2011]Management of anemia in HCV patients: Timing is everything2011-02-23

[APASL2011]Management of Hepatitis B from Asia-Pacific and Western Region Perspective : We Are Seeking Common Ground2011-02-23

[APASL2011]Statins for the treatment of NASH?2011-02-23

[APASL2011]Molecular Markers in the Diagnosis and Prognostic Staging of HCC2011-02-23

[APASL2011]Roles of Endoscopy in Hilar Biliary Obstruction2011-02-23



设为首页 | 加入收藏 | 网站地图 | 订阅杂志 | 关于我们 | 版权声明 | 联系方式|招贤纳士
国际肝病  版权所有  京ICP备15060708号   (京)-非经营性-2016-0001京公网安备 11010502033341号 2004-2020  www.ihepa.com  ALL Rights  Reserved

增值电信业务经营许可证:京B2-20212326

网站统计